Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 9, 2008

Celera to Separate from Applera on July 1

  • The board of directors at Applera formally approved the proposed separation of the Celera Group from its remaining businesses. The separation will be accomplished by means of a redemption of all of the outstanding shares of Applera-Celera Group tracking stock.

    In the redemption, each outstanding share of Celera Group tracking stock will be redeemed in exchange for one share of common stock of Celera. Upon completion of the separation, Celera will hold all of the businesses, assets, and liabilities attributed to the Celera Group and will be an independent, publicly traded company whose shares are expected to be listed on The NASDAQ Stock Market.

    The separation is expected to be completed at 12:01 a.m. ET, on July 1, 2008, subject to a number of conditions. Kathy Ordoñez, currently president of the Celera Group, will serve as Celera’s CEO, and the company’s corporate headquarters will be based in Alameda, California.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »